New hope for older leukemia patients with gentler drug combo
NCT ID NCT04657081
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia. About 101 people will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207, United States
-
Baylor Scott & White Research Institute
Temple, Texas, 76508, United States
-
Boca Raton Clinical Research
Plantation, Florida, 33322, United States
-
Clinica Universidad de Navarra, Pamplona
Pamplona, Navarre, 31008, Spain
-
East Carolina University
Greenville, North Carolina, 27834, United States
-
Hackensack University of Medical Center
Hackensack, New Jersey, 07601, United States
-
Health Midwest Ventures Group, Inc.
Kansas City, Missouri, 64132, United States
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Central de Asturias
Oviedo, Austrias, 33011, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Indiana University Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Institut Catala d'Oncologia-Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Jewish General Hospital
Montreal, H3T 1E2, Canada
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Stanford University
Palo Alto, California, 94306, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
The Ottawa Hospital, General Campus
Ottawa, Ontario, K1H 8L6, Canada
-
The Research Foundation of the State University of New York (SUNY)
Syracuse, New York, 13210, United States
-
The University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Universitario Gregorio Marañon
Madrid, 28007, Spain
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
-
University of Calgary - Health Sciences Centre
Calgary, Alberta, T2N 4N1, Canada
-
University of Massachusetts, Memorial Medical Center
Worcester, Massachusetts, 01655, United States
-
University of Rochester
Rochester, New York, 14627, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-6307, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
Yale University
New Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?